Literature DB >> 6487512

Measurement of antipyrine half-life from urinary drug concentrations.

G Taylor, T F Blaschke.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6487512      PMCID: PMC1463628          DOI: 10.1111/j.1365-2125.1984.tb02524.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.

Authors:  E S Vesell; G T Passananti; P A Glenwright; B H Dvorchik
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

2.  Elimination of antipyrine from saliva as a measure of metabolism in man.

Authors:  R M Welch; R L DeAngelis; M Wingfield; T W Farmer
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

3.  Assessment of antipyrine kinetics by measurement in saliva.

Authors:  H S Fraser; J C Mucklow; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

4.  Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Authors:  M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

5.  Drug urinary excretion data--some aspects concerning the interpretation.

Authors:  B K Martin
Journal:  Br J Pharmacol Chemother       Date:  1967-02

6.  Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.

Authors:  M Eichelbaum; L Bertilsson; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

7.  Differential induction of antipyrine metabolism by rifampicin.

Authors:  E L Toverud; A R Boobis; M J Brodie; S Murray; P N Bennett; V Whitmarsh; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

8.  Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.

Authors:  M Danhof; E de Groot-van der Vis; D D Breimer
Journal:  Pharmacology       Date:  1979       Impact factor: 2.547

  8 in total
  4 in total

1.  Ethical considerations in the conduct of clinical pharmacokinetic studies.

Authors:  C K Svensson
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

2.  Plasma antipyrine half-life can be determined from urine data.

Authors:  J O Atiba; G Taylor; R A Pershe; T F Blaschke
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

Review 3.  Effect of acute and chronic exercise on hepatic drug metabolism.

Authors:  M Døssing
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

4.  Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance.

Authors:  Daniel Scotcher; Christopher Jones; Amin Rostami-Hodjegan; Aleksandra Galetin
Journal:  Eur J Pharm Sci       Date:  2016-03-28       Impact factor: 4.384

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.